AIM ImmunoTech Inc

Financials

Activos totales 64.58 M57.7 M40.49 M19.38 M8.61 M5.78 M Total de pasivos 3.11 M785 K2.02 M9.15 M9.93 M15.56 M Capital total 61.29 M56.88 M38.47 M10.23 M-1.32 M-9.78 M Total de pasivos y patrimonio neto 64.58 M57.7 M40.49 M19.38 M8.61 M5.78 M Deuda total 2.11 M0——2.31 M4.48 M Deuda neta -52.85 M-48.12 M——-3.34 M-1.7 M

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.

AIM

Financials

AIM ImmunoTech Inc

Noticias

AIM ImmunoTech modifica acuerdo de distribución de acciones para eliminar límite de venta

Diapositivas T4 2025 de Aimia: desinversión liberará 265 millones de dólares pese a ingresos decepcionantes

Informe de resultados: Aimia Inc. no alcanza las previsiones del cuarto trimestre de 2025, la acción sube

What's Going On With AIM ImmunoTech Stock Friday? - AIM ImmunoTech (AMEX:AIM)

AIM ImmunoTech completa oferta de derechos y crea nueva serie de acciones preferentes

AIM ImmunoTech completes rights offering, creates new preferred stock series

Indonesia Sees $11 Billion in Share Sales to Meet Free-Float Aim

AIM ImmunoTech en Virtual Investor Closing Bell: enfoque estratégico en cáncer de páncreas

AIM ImmunoTech en Virtual Investor: Enfoque en cáncer pancreático

AIM ImmunoTech at Virtual Investor Closing Bell: Strategic Focus on Pancreatic Cancer

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories! - TipRanks.com

Bets on Surprise ECB Cut in 2026 Aim for 12-Fold Return